1. A display device comprising a plurality of arranged pixels, each of which includes an electro-optical component, a write-in transistor for writing an image signal into the pixel, a maintenance capacity element for maintaining the image signal written by the write-in transistor, and a driving transistor for driving the electro-optical component based on the image signal maintained by the maintenance capacity element,
wherein,
the write-in transistor has a plurality of gates,
a driving transistor side gate from among the plurality of gates has a structure in which a channel region is sandwiched between a first gate electrode and a second gate electrode,
the width of the channel region of the driving transistor side gate is narrower than the width of the channel region of each of the other gates, and
except for the driving transistor side gate, the gates are shielded by a metal wiring layer.
2. The display device according to claim 1, wherein the second gate electrode has a width that is narrower than a width of the first gate electrode.
3. The display device according to claim 1, wherein the second gate electrode is formed of the same wiring material as a signal line for transmitting the image signal.
4. The display device according to claim 1, wherein the write-in transistor has an LDD structure in which an impurity region having a density that is lower than that of a sourcedrain region is provided between the sourcedrain region and a channel region.
5. The display device according to claim 4, wherein the second gate electrode does not overlap the impurity region.
6. The display device according to claim 1, wherein, in the write-in transistor, a parasitic capacitance exists between the channel region and the second gate electrode, and the capacitance value of the parasitic capacitance is one parameter that determines a gain during a bootstrap operation in which a gate potential of the driving transistor is changed to follow a source potential of the driving transistor when the write-in transistor is in a non-conductive state.
7. The display device according to claim 6, wherein the source potential of the driving transistor is changed according to a current flowing through the driving transistor.
8. An electronic appliance comprising: a display device including a plurality of arranged pixels, each of which includes an electro-optical component, a write-in transistor for writing an image signal into the pixel, a maintenance capacity element for maintaining the image signal written by the write-in transistor, and a driving transistor for driving the electro-optical component based on the image signal maintained by the maintenance capacity element,
wherein,
the write-in transistor has a plurality of gates, the driving transistor-side gate from among the plurality of gates has a structure in which a channel region is sandwiched between a first gate electrode and a second gate electrode, and a width of the channel region of the driving transistor-side gate is narrower than a width of the channel region of each of the other gates, and
except for the driving transistor-side gate, the plurality of gates are shielded by a metal wiring layer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of structure A:
wherein:
G1 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl;
the moiety L1-L2 is selected from a group consisting of:
A1 is selected from a group consisting of a bond, NRa, C(O), S(O), S(O)2, P(O)2, O, S, and C(Ra)2, wherein if A1 is a bond, then the phenyl ring is directly connected to the group A2;
A2 is selected from a group consisting of NR, C(O), S(O), S(O)2, P(O)2, O, and S; and the connectivity between the phenyl ring, A1, A2 and the pyrimidine ring are chemically correct;
Ra is selected from a group consisting of H, lower alkyl, branched alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, alkylhydroxyl, alklythiol, and alkylamino;
R3 is selected independently for each occurrence from a group consisting of hydrogen, alkyl, branched alkyl, alkoxy, halogen, CF3, cyano, substituted alkyl, hydroxyl, alkylhydroxyl, thiol, alkylthiol, thioalkyl, amino, and aminoalkyl;
n is an integer having value between 0 and 4 inclusive;
the moiety
is selected from a group consisting of:
L5 is selected from a group consisting of lower alkyl, branched alkyl, CF3, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, bicyclic aryl, bicyclic heteroaryl, bicyclic with one of the rings being aryl or heteroaryl and the other ring being nonaryl, and bicyclic with both rings being nonaryl;
wherein an optionally substituted aryl or heteroaryl, independently for each occurrence, can be substituted on 1, 2, 3, or 4 carbons by alkyl, branched alkyl, alkoxy, halogen, CF3, cyano, substituted alkyl, hydroxyl, alkylhydroxyl, thiol, alkylthiol, thioalkyl, amino, and aminoalkyl;
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound of claim 1 having the structure
wherein X is selected from a group consisting of CH and N.
3. The compound of claim 1 having the structure
wherein each of A1 and A2 is independently selected from a group consisting of C\u2550O and NH, with the further proviso that when A1 is NH, A2 is C\u2550O, and when A2 is NH, A1 is C\u2550O.
4. The compound of claim 3 having the structure
5. The compound of claim 4, wherein L5 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl.
6. The compound of claim 3 having the structure
wherein L5 is selected from a group consisting of an optionally substituted aryl or an optionally substituted heteroaryl.
7. The compound of claim 6, wherein L5 is an optionally substituted aryl.
8. A compound having the structure:
wherein L5 is a phenyl optionally substituted on 1, 2, 3, 4, or 5 carbons with halogen, alkyl, or CF3;
X is N or CH; and
the moiety L1-L2 is selected from a group consisting of \u2014SO2-alkyl-heterocycle, \u2014SO2NH-alkyl-heterocycle; SO2-heterocycle, \u2014O-alkyl-heterocycle; \u2014C(O)N-alkyl-heterocycle, \u2014C(O)-alkylheterocycle, -alkyl-heterocycle; \u2014O-alkyl; \u2014C(O)O-alkyl; \u2014OH; \u2014OC(O)-phenyl; wherein the heterocycle or the phenyl can be optionally substituted with alkyl, alkoxy, hydroxyalkyl, or halogen;
or a pharmaceutically acceptable salt or stereoisomer thereof.
9. The compound of claim 8, wherein the optionally substituted heterocycle is selected from a group consisting of azetidine, pyrrolidine, morpholine, piperidine, piperazine, azepane, diazepane, and azocane.
10. A compound having the structure
wherein L5 is phenyl, optionally substituted with methyl, halogen, or CF3;
R3 is selected from a group consisting of methyl and chloro, and
X is selected from a group consisting of CH and N; or a pharmaceutically acceptable salt, or stereoisomer thereof.
11. The compound of claim 1, wherein the compound is selected from the group consisting of compounds X, XLV, XL, XXXVIII, and XXXIX, or a pharmaceutically acceptable salt thereof:
12. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XXVIII and XLIV, or a pharmaceutically acceptable salt thereof:
13. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XLIII and XXXIV, or a pharmaceutically acceptable salt thereof:
14. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XVI, XVII, XX, and XXII, or a pharmaceutically acceptable salt thereof:
15. The compound of claim 1, wherein the compound is compound XXIII, or a pharmaceutically acceptable salt thereof:
16. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XVIII and XIX, or a pharmaceutically acceptable salt thereof:
17. The compound of claim 1, wherein the compound is compound XXI, or a pharmaceutically acceptable salt thereof:
18. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XXX and XXXI, or a pharmaceutically acceptable salt thereof:
19. The compound of claim 1, wherein the compound is selected from the group consisting of compounds I, II, III, and IV, or a pharmaceutically acceptable salt thereof:
20. The compound of claim 1, wherein the compound is selected from the group consisting of compounds VII, XI, XII, XIII, XIV, and XV, or a pharmaceutically acceptable salt thereof:
21. The compound of claim 1, wherein the compound is compound LII, or a pharmaceutically acceptable salt thereof:
22. The compound of claim 1, wherein the compound is compound XXIX, or a pharmaceutically acceptable salt thereof:
23. The compound of claim 1, wherein the compound is selected from the group consisting of compounds VIII and IX, or a pharmaceutically acceptable salt thereof:
24. The compound of claim 1, wherein the compound is compound XLVII, or a pharmaceutically acceptable salt thereof:
25. The compound of claim 1, wherein the compound is compound V, or a pharmaceutically acceptable salt thereof:
26. The compound of claim 1, wherein the compound is compound XLVI, or a pharmaceutically acceptable salt thereof:
27. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XLI and XLII, or a pharmaceutically acceptable salt thereof:
28. The compound of claim 1, wherein the compound is compound XXXVII, or a pharmaceutically acceptable salt thereof:
29. The compound of claim 1, wherein the compound is selected from the group consisting of compounds XXXII and XXIII, or a pharmaceutically acceptable salt thereof:
30. The compound of claim 1, wherein the compound is compound XL, or a pharmaceutically acceptable salt thereof:
31. The compound of claim 1, wherein the compound is selected from the group consisting of compounds LVI, LVII, and LX-LXIII, or a pharmaceutically acceptable salt thereof:
32. A pharmaceutical composition comprising at least one compound represented by structure A according to claim 1 and a pharmaceutically acceptable carrier.
33. The pharmaceutical composition of claim 32, wherein said composition is suitable for oral administration, intravenous administration, topical administration, ocular administration or subcutaneous administration.
34. The pharmaceutical composition of claim 32, wherein said composition is suitable for ocular administration.